NASDAQ:MNOV - MediciNova Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding MediciNova, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $6.27 +0.17 (+2.79 %) (As of 01/29/2020 06:00 AM ET) Add Compare Today's Range$6.14Now: $6.27▼$6.2750-Day Range$6.10MA: $6.88▼$7.8752-Week Range$6.06Now: $6.27▼$13.37Volume69,185 shsAverage Volume63,505 shsMarket Capitalization$274.89 millionP/E RatioN/ADividend YieldN/ABeta1.16 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email MediciNova, Inc, a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:MNOV Previous Symbol CUSIPN/A CIK1226616 Webhttp://medicinova.com/ Phone858-373-1500Debt Debt-to-Equity RatioN/A Current Ratio36.49 Quick Ratio36.49Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.75 per share Price / Book3.58Profitability EPS (Most Recent Fiscal Year)($0.36) Net Income$-14,670,000.00 Net MarginsN/A Return on Equity-15.11% Return on Assets-14.35%Miscellaneous Employees9 Outstanding Shares43,842,000Market Cap$274.89 million Next Earnings Date2/12/2020 (Estimated) OptionableOptionable Receive MNOV News and Ratings via Email Sign-up to receive the latest news and ratings for MNOV and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:MNOV Rates by TradingView MediciNova (NASDAQ:MNOV) Frequently Asked Questions What is MediciNova's stock symbol? MediciNova trades on the NASDAQ under the ticker symbol "MNOV." How were MediciNova's earnings last quarter? MediciNova, Inc. (NASDAQ:MNOV) announced its earnings results on Thursday, October, 29th. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.10) by $0.04. View MediciNova's Earnings History. When is MediciNova's next earnings date? MediciNova is scheduled to release their next quarterly earnings announcement on Wednesday, February 12th 2020. View Earnings Estimates for MediciNova. What price target have analysts set for MNOV? 1 equities research analysts have issued 1 year price objectives for MediciNova's stock. Their forecasts range from $22.00 to $22.00. On average, they anticipate MediciNova's stock price to reach $22.00 in the next twelve months. This suggests a possible upside of 250.9% from the stock's current price. View Analyst Price Targets for MediciNova. What is the consensus analysts' recommendation for MediciNova? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MediciNova in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for MediciNova. Has MediciNova been receiving favorable news coverage? Media headlines about MNOV stock have been trending negative this week, InfoTrie reports. The research firm identifies positive and negative media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. MediciNova earned a news impact score of -2.1 on InfoTrie's scale. They also assigned media headlines about the biopharmaceutical company a news buzz of 3.0 out of 10, meaning that recent media coverage is unlikely to have an impact on the company's share price in the immediate future. View News Stories for MediciNova. Are investors shorting MediciNova? MediciNova saw a decrease in short interest in January. As of January 15th, there was short interest totalling 2,940,000 shares, a decrease of 8.1% from the December 31st total of 3,200,000 shares. Based on an average daily trading volume, of 107,700 shares, the days-to-cover ratio is currently 27.3 days. Currently, 8.0% of the shares of the company are short sold. View MediciNova's Current Options Chain. Who are some of MediciNova's key competitors? Some companies that are related to MediciNova include Enanta Pharmaceuticals (ENTA), Opko Health (OPK), Portola Pharmaceuticals (PTLA), Phibro Animal Health (PAHC), Dermira (DERM), NextCure (NXTC), Karyopharm Therapeutics (KPTI), Revance Therapeutics (RVNC), XBiotech (XBIT), Odonate Therapeutics (ODT), Akebia Therapeutics (AKBA), Amphastar Pharmaceuticals (AMPH), Applied Therapeutics (APLT), RAPT Therapeutics (RAPT) and Gossamer Bio (GOSS). What other stocks do shareholders of MediciNova own? Based on aggregate information from My MarketBeat watchlists, some companies that other MediciNova investors own include Novavax (NVAX), Progenics Pharmaceuticals (PGNX), Amicus Therapeutics (FOLD), Geron (GERN), NovaBay Pharmaceuticals (NBY), Cytokinetics (CYTK), Immunomedics (IMMU), Inovio Pharmaceuticals (INO), Opko Health (OPK) and Pieris Pharmaceuticals (PIRS). Who are MediciNova's key executives? MediciNova's management team includes the folowing people: Dr. Yuichi Iwaki, Co-Founder, Pres, CEO & Exec. Director (Age 69)Mr. Masatsune Okajima, Head of Japanese Office & VP (Age 51)Dr. Kazuko Matsuda M.P.H., M.D., Ph.D., MPH, Chief Medical Officer (Age 53)Ms. Carla Reyes, Chief Financial Officer (Age 47)Mr. John O'Neil CPA, Controller Who are MediciNova's major shareholders? MediciNova's stock is owned by many different of retail and institutional investors. Top institutional investors include California Public Employees Retirement System (0.19%) and Alpine Global Management LLC (0.03%). View Institutional Ownership Trends for MediciNova. Which major investors are buying MediciNova stock? MNOV stock was acquired by a variety of institutional investors in the last quarter, including California Public Employees Retirement System and Alpine Global Management LLC. View Insider Buying and Selling for MediciNova. How do I buy shares of MediciNova? Shares of MNOV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is MediciNova's stock price today? One share of MNOV stock can currently be purchased for approximately $6.27. How big of a company is MediciNova? MediciNova has a market capitalization of $274.89 million. The biopharmaceutical company earns $-14,670,000.00 in net income (profit) each year or ($0.36) on an earnings per share basis. MediciNova employs 9 workers across the globe.View Additional Information About MediciNova. What is MediciNova's official website? The official website for MediciNova is http://medicinova.com/. How can I contact MediciNova? MediciNova's mailing address is 4275 EXECUTIVE SQUARE SUITE 300, LA JOLLA CA, 92037. The biopharmaceutical company can be reached via phone at 858-373-1500 or via email at [email protected] MarketBeat Community Rating for MediciNova (NASDAQ MNOV)Community Ranking: 2.7 out of 5 ( )Outperform Votes: 186 (Vote Outperform)Underperform Votes: 162 (Vote Underperform)Total Votes: 348MarketBeat's community ratings are surveys of what our community members think about MediciNova and other stocks. Vote "Outperform" if you believe MNOV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MNOV will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/29/2020 by MarketBeat.com StaffFeatured Article: Does a trade war provide a risk to the global economy?
